Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections

被引:98
作者
Van Eldere, J [1 ]
机构
[1] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Rega Inst, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Microbiol Lab, B-3000 Louvain, Belgium
关键词
Pseudomonas aeruginosa; nosocomial infections; susceptibility rates; surveillance;
D O I
10.1093/jac/dkg102
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To determine susceptibility rates and patterns in Pseudomonas aeruginosa strains isolated from nosocomial infections. Methods: Seven hundred and sixteen P. aeruginosa isolates from 40 different hospitals in Belgium and the Grand Duchy of Luxembourg were collected in 1999. Results: Resistance rates varied significantly between hospitals. Of the fluoroquinolones, ciprofloxacin showed least resistance (24%), levofloxacin showed 27.5% resistance and ofloxacin 37.5%. Of the aminoglycosides, amikacin was the most potent antibiotic (10.5% resistance), followed by isepamicin (12%), tobramycin (19.5%) and gentamicin (23.5%). Of the beta-lactam antibiotics, meropenem was the most active (9.5% resistance); piperacillin and piperacillin/tazobactam had, respectively, 24% and 17.5% resistance, ceftazidime 28.5%, cefepime 29.5%, ticarcillin/clavulanic acid 37% and aztreonam 55.5%. MIC distribution curves show the presence of significant subpopulations, with MICs just below breakpoint for many antibiotics. Conclusion: Resistance of P. aeruginosa to penicillins, cephalosporins, fluoroquinolones and aminoglycosides varies between hospitals, but is increasing.
引用
收藏
页码:347 / 352
页数:6
相关论文
共 21 条
[1]  
ALLOUCH P, 1999, CLIN MICROBIOLOGY S3, V5, P239
[2]   DEVELOPMENT OF RESISTANCE TO IMIPENEM AMONG NOSOCOMIAL ISOLATES OF PSEUDOMONAS-AERUGINOSA [J].
BASUSTAOGLU, AC ;
GUN, H ;
SARACLI, MA ;
BAYSALLAR, M ;
HAZNEDAROGLU, T .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (05) :469-470
[3]  
Bert F, 1996, PATHOL BIOL, V44, P329
[4]  
BOFFI E, 2000, CLIN MICROBIOL INFEC, V6, P119
[5]   In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams [J].
Bonfiglio, G ;
Marchetti, F .
CHEMOTHERAPY, 2000, 46 (04) :229-234
[6]   Antibiotic resistance in Pseudomonas aeruginosa:: an Italian survey [J].
Bonfiglio, G ;
Carciotto, V ;
Russo, G ;
Stefani, S ;
Schito, GC ;
Debbia, E ;
Nicoletti, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) :307-310
[7]   Pseudomonas aeruginosa:: a survey of resistance in 136 hospitals in Spain [J].
Bouza, E ;
Garcia-Garrote, F ;
Cercenado, E ;
Marin, M ;
Diaz, MS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :981-982
[8]   Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents [J].
Carmeli, Y ;
Troillet, N ;
Eliopoulos, GM ;
Samore, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1379-1382
[9]   Antimicrobial resistance in intensive care units [J].
Fridkin, SK ;
Gaynes, RP .
CLINICS IN CHEST MEDICINE, 1999, 20 (02) :303-+
[10]  
GARBINO J, 2000, CLIN MICROBIOL INFEC, V6, P46